Diabetes-associated MicroRNAs in pediatric patients with type 1 diabetes mellitus: A cross-sectional cohort study

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 9, 2014, Pages E1661-E1665

  Osipova, Julia ^a   Fischer, Dagmar Christiane ^b   Dangwal, Seema ^a   Volkmann, Ingo ^a   Widera, Christian ^a   Schwarz, Katrin ^a   Lorenzen, Johan M ^a   Schreiver, Corinna ^b   Jacoby, Ulrike ^b   Heimhalt, Mirjam ^b   Thum, Thomas ^a,c   Haffner, Dieter ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; MICRORNA 126; MICRORNA 21; MICRORNA 210; BIOLOGICAL MARKER; MICRORNA; MIRN126 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN; MIRN219 MICRORNA, HUMAN;

ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR RISK; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; UPREGULATION; URINALYSIS; ADOLESCENT; BLOOD; DIABETES MELLITUS, TYPE 1; DOWN REGULATION; GENETICS; HYPERGLYCEMIA; ONSET AGE; RECEIVER OPERATING CHARACTERISTIC; URINE;

ADOLESCENT; AGE OF ONSET; BIOLOGICAL MARKERS; CHILD; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DOWN-REGULATION; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; MICRORNAS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84907211338     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3868     Document Type: Article

References (23)

1. Morrish NJ,WangSL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in theWHOmultinational study of vascular disease in diabetes. Diabetologia 2001;44(suppl 2): S14-S21.
2. Makinen VP, Forsblom C, ThornLM,et al. FinnDiane Study Group. Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes 2008;57(9): 2480-2487.
3. Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011;51(5): 872-875.
4. Lorenzen JM, Volkmann I, Fiedler J, et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am J Transplant. 2011;11(10): 2221-2227.
5. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224): 980-984.
6. Kumarswamy R, Volkmann I, Jazbutyte V, Dangwal S, Park DH, Thum T. Transforming growth factor-induced endothelial-tomesenchymal transition is partly mediated by microRNA-21. Arterioscler Thromb Vasc Biol. 2012;32(2): 361-369.
7. DeyN, Das F, MariappanMM,et al. MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J Biol Chem. 2011;286(29): 25586-25603.
8. Zhong X, Chung AC, Chen HY, et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia. 2013;56(3): 663-674.
9. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15(2): 261-271.
10. Fish JE, SantoroMM,Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15(2): 272-284.
11. Long J, Wang Y, Wang W, Chang BH, Danesh FR. Identification of microRNA- 93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem. 2010;285(30): 23457-23465.
12. Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107(5): 677-684.
13. Zampetaki A, Kiechl S, Drozdov I, et al. PlasmamicroRNAprofiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107(6): 810-817.
14. Greco S, Fasanaro P, Castelvecchio S, et al. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes. 2012;61(6): 1633-1641.
15. Argyropoulos C, Wang K, McClarty S, et al. Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLoS One. 2013; 8(1): E54662.
16. Wang G, Kwan BC, Lai FM, Chow KM, Li PK, Szeto CC. Urinary sediment miRNA levels in adult nephrotic syndrome. Clin Chim Acta. 2013;418: 5-11.
17. Martino F, Lorenzen J, Schmidt J, et al. Circulating microRNAs are not eliminated by hemodialysis. PLoS One. 2012;7(6): E38269.
18. Miranda KC, Bond DT, McKee M, et al. Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. Kidney Int. 2010;78(2): 191-199.
19. Chau BN, Xin C, Hartner J, et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med. 2012;4(121): 121ra18.
20. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987;59(8): 750-755.
21. Snell-Bergeon JK, Maahs DM, Ogden LG, et al. Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther. 2009;11(1): 1-9.
22. Karalliedde J, Viberti G. Proteinuria in diabetes: Bystander or pathway to cardiorenal disease? J Am Soc Nephrol. 2010;21(12): 2020-2027.
23. Harvey SJ, Jarad G, Cunningham J, et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol. 2008;19(11): 2150-2158.